Arcadia Biosciences (RKDA)
NASDAQ:RKDA
RKDA Stock Chart & Stats
$3.21
-$0.31(-5.28%)
At close: 4:00 PM EST
$3.21
-$0.31(-5.28%)
Day’s Range― - ―
52-Week Range$1.46 - $6.71
Previous CloseN/A
Volume12.29K
Average Volume (3M)1.09M
Market Cap
$2.63M
Enterprise Value$1.75M
Total Cash (Recent Filing)$4.56M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.03
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding1,729,884
10 Day Avg. Volume3,254,407
30 Day Avg. Volume1,090,692
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.65
Price to Sales (P/S)0.56
P/FCF Ratio-0.57
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue0.36
Enterprise Value/Gross Profit0.99
Enterprise Value/Ebitda-0.54
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.42
Revenue Forecast (FY)$7.70M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceQ4’24 results were ahead of expectations behind Zola coconut water growth of 124% via an 86% distribution increase.
Market ExpansionZola’s 80% distribution expansion in 2024 to approximately 3,000 stores is providing considerable visibility for year-over-year growth.
Bears Say
Portfolio MonetizationManagement noted they continue to seek further monetization of legacy ag biotech IP and expect a series of transactions to unwind this portfolio.
Valuation ConcernArcadia's current valuation levels are considered materially depressed relative to a post-merger fair value, making it an attractive option for special situation and/or merger arbitrage investors.
Arcadia Biosciences News
RKDA FAQ
What was Arcadia Biosciences’s price range in the past 12 months?
Arcadia Biosciences lowest stock price was $1.46 and its highest was $6.71 in the past 12 months.
What is Arcadia Biosciences’s market cap?
Arcadia Biosciences’s market cap is $2.63M.
When is Arcadia Biosciences’s upcoming earnings report date?
Arcadia Biosciences’s upcoming earnings report date is May 07, 2026 which is in 40 days.
How were Arcadia Biosciences’s earnings last quarter?
Arcadia Biosciences released its earnings results on Mar 26, 2026. The company reported -$0.97 earnings per share for the quarter, missing the consensus estimate of -$0.66 by -$0.31.
Is Arcadia Biosciences overvalued?
According to Wall Street analysts Arcadia Biosciences’s price is currently Overvalued.
Does Arcadia Biosciences pay dividends?
Arcadia Biosciences does not currently pay dividends.
What is Arcadia Biosciences’s EPS estimate?
Arcadia Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arcadia Biosciences have?
Arcadia Biosciences has 1,729,884 shares outstanding.
What happened to Arcadia Biosciences’s price movement after its last earnings report?
Arcadia Biosciences reported an EPS of -$0.97 in its last earnings report, missing expectations of -$0.66. Following the earnings report the stock price went down -3.289%.
Which hedge fund is a major shareholder of Arcadia Biosciences?
Currently, no hedge funds are holding shares in RKDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Arcadia Biosciences
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.
Technical Analysis
American Vanguard
―
Origin Agritech
―
BioHarvest Sciences
―
Bioceres Crop Solutions
―
―
Ownership Overview
0.32%
Insiders
1.15% Mutual Funds
0.58% Other Institutional Investors
97.40% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---